PCSK9 Forum
December 2014
Facebook Twitter RSS
For latest updates
Register today
Home About PCSK9 Forum News Expert Opinion Education & Resources Register
PCSK9 Education and Research Forum:
December 2014

New on PCSK9 Education and Research Forum

Videos from the Inaugural Editorial Board Meeting:
State-of-the-Art PCSK9 Science:
Current understanding and therapeutic perspectives

Familial hypercholesterolaemia: putting the patient first


Katherine Wilemon, CEO of the FH Foundation highlights the invisibility of FH patients and why patient advocacy can make a difference.
‘To improve awareness of FH, we need to involve all players in the FH field, using both top-down and bottom-up approaches’

For more about the FH Foundation: www.thefhfoundation.org

PCSK9 Science


Prof Bertrand Cariou, INSERM UMR1087, l’Institut du Thorax, Nantes, France
Does PCSK9 have effects beyond the liver and if so, what is the evidence?


Prof Anne Tybjaerg-Hansen, Rigshospitalet, Copenhagen University Hospital, and University of Copenhagen, Denmark
Loss of function mutations in PCSK9: the trigger for therapeutic development

Translating Science to the Clinic


Prof Steve Nicholls, South Australian Health and Medical Research Institute and University of Adelaide, Australia
Does PCSK9 inhibition impact atherosclerosis?
Would imaging help to refine clinical management of the high risk patient?

Freezeframe of video, Ginsberg

Prof Henry Ginsberg, University of Columbia, New York, USA
PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor

Societal Implications: Addressing Unmet Needs in Cholesterol Management


Prof Henry Ginsberg, University of Columbia, New York, USA
What are the patient priorities for PCSK9 inhibitors?


Prof Luis Masana, University Rovira and Virgili, Reus-Tarragona, Spain
High cholesterol: an unmet need
Weighing the cost versus benefit of PCSK9-targeted therapy

Looking ahead with PCSK9 Education & Research Forum


Co-Editor Professor Henry Ginsberg, University of Columbia, New York, USA gives his views
About PCSK9 Education and Research Forum

Watch the Aims & Objectives video
Read our Mission Statement
Partnership and outreach
Meet our Editorial Board
View Forthcoming Meetings
Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite link

News from AHA Scientific Sessions 2014 More from ODYSSEY: ODYSSEY COMBO, OPTIONS I and OPTIONS...
News from AHA Scientific Sessions 2014 More from ODYSSEY: ODYSSEY LONG TERM
AHA Scientific Sessions 2014: The Editors view of Day 2
News from AHA Scientific Sessions 2014 – Heterozygous FH: Do we need a genetic diagnosis?

Read more news »
New PCSK 9 agents may revolutionise management of #cholesterol. Stay in touch with news and expert comment. www.pcsk9forum.org

Exciting new research in fast-moving lipid research with PCSK9. Stay in touch with global experts Register now www.pcsk9forum.org


News from AHA Scientific Sessions 2014 - Heterozygous FH: Do we need a genetic diagnosis? http://www.pcsk9forum.org/ news-from-aha-scientific-sessions-2014-heterozygous- fh-do-we-need-a-genetic-diagnosis/ #KnowFH

#AHAScientificSessions2014 #Familial #hypercholesterolaemia #USprevalence one in 299 people according to #NHANESdata

#AHAScientificSessions2014 More #ODYSSEY trials to report today check back on #PCSK9Forum for discussion

#AHAScientificSessions2014< overview of key #posters by #ProfDerickRaal

#AHAScientificSessions2014 #HeFH: genotype versus phenotype for #diagnosis? #ProfDerickRaal
Our mission

Our goal
PCSK9 Education and Research Forum is the major, globally-recognised resource of independent knowledge of PCSK9 science and its translation to therapeutic innovation. Our mission is to facilitate development of these new treatments in order to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease.

Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes.
  Supported by educational grants from: Amgen Lilly pFizer Sanofi  
Copyright PCSK9 Forum 2014. Please click here to unsubscribe from future mailings.